These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 8615904

  • 1. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
    Shivachar AC, Martin BR, Ellis EF.
    Biochem Pharmacol; 1996 Mar 08; 51(5):669-76. PubMed ID: 8615904
    [Abstract] [Full Text] [Related]

  • 2. Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes.
    Shivachar AC.
    Biochem Pharmacol; 2007 Jun 15; 73(12):2004-11. PubMed ID: 17445778
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
    Smith FL, Fujimori K, Lowe J, Welch SP.
    Pharmacol Biochem Behav; 1998 May 15; 60(1):183-91. PubMed ID: 9610941
    [Abstract] [Full Text] [Related]

  • 5. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
    Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, Arthur DB, Wilson DM, Martin BR.
    Eur J Pharmacol; 1998 Sep 18; 357(2-3):139-48. PubMed ID: 9797029
    [Abstract] [Full Text] [Related]

  • 6. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA, Járai Z, Bátkai S, Kunos G.
    Eur J Pharmacol; 2001 Jul 06; 423(2-3):203-10. PubMed ID: 11448486
    [Abstract] [Full Text] [Related]

  • 7. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
    Järbe TU, Lamb RJ, Lin S, Makriyannis A.
    Psychopharmacology (Berl); 2001 Aug 06; 156(4):369-80. PubMed ID: 11498713
    [Abstract] [Full Text] [Related]

  • 8. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.
    Mallet PE, Beninger RJ.
    Psychopharmacology (Berl); 1998 Nov 06; 140(1):11-9. PubMed ID: 9862397
    [Abstract] [Full Text] [Related]

  • 9. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.
    Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE.
    J Neurochem; 1998 Feb 06; 70(2):671-6. PubMed ID: 9453561
    [Abstract] [Full Text] [Related]

  • 10. The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes.
    Oz M, Yang KH, Dinc M, Shippenberg TS.
    J Pharmacol Exp Ther; 2007 Nov 06; 323(2):547-54. PubMed ID: 17682128
    [Abstract] [Full Text] [Related]

  • 11. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
    Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR, Yamamura HI.
    Eur J Pharmacol; 1997 Oct 08; 336(2-3):295-8. PubMed ID: 9384246
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
    Calignano A, La Rana G, Beltramo M, Makriyannis A, Piomelli D.
    Eur J Pharmacol; 1997 Oct 15; 337(1):R1-2. PubMed ID: 9389389
    [Abstract] [Full Text] [Related]

  • 13. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
    Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Ségui M, Casellas P.
    FEBS Lett; 1998 Apr 03; 425(3):419-25. PubMed ID: 9563506
    [Abstract] [Full Text] [Related]

  • 14. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR.
    Psychopharmacology (Berl); 2009 Apr 03; 203(2):219-28. PubMed ID: 18592221
    [Abstract] [Full Text] [Related]

  • 15. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
    Fernández-Ruiz JJ, Muñoz RM, Romero J, Villanua MA, Makriyannis A, Ramos JA.
    Biochem Pharmacol; 1997 Jun 15; 53(12):1919-27. PubMed ID: 9256167
    [Abstract] [Full Text] [Related]

  • 16. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential.
    Aceto MD, Scates SM, Razdan RK, Martin BR.
    J Pharmacol Exp Ther; 1998 Nov 15; 287(2):598-605. PubMed ID: 9808686
    [Abstract] [Full Text] [Related]

  • 17. Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.
    Kangas BD, Leonard MZ, Shukla VG, Alapafuja SO, Nikas SP, Makriyannis A, Bergman J.
    J Pharmacol Exp Ther; 2016 Apr 15; 357(1):125-33. PubMed ID: 26826191
    [Abstract] [Full Text] [Related]

  • 18. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells.
    Basavarajappa BS, Hungund BL.
    J Neurochem; 1999 Feb 15; 72(2):522-8. PubMed ID: 9930723
    [Abstract] [Full Text] [Related]

  • 19. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes.
    Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C.
    Eur J Neurosci; 1999 Feb 15; 11(2):691-9. PubMed ID: 10051770
    [Abstract] [Full Text] [Related]

  • 20. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
    Costa B, Colleoni M.
    Eur J Pharmacol; 2000 Apr 21; 395(1):1-7. PubMed ID: 10781666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.